Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Study ID
NCT02628067

Study type
Interventional

Study phase
Phase 2

Study status
Recruiting

Trial Acronym

Trial Summary

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

More informations

Trial Starting Date

Dec 18,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

1609